Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Bioavailability Clinical Trial

Official title: A 3-way, Crossover, Randomized, Open-label Study in Healthy Subjects Comparing the Bioavailability of Belumosudil (KD025) Tablets in Fed and Fasted States and Relative Bioavailability of Tablets and Capsules in the Fed State

Status Completed

Clinical Trial Summary

Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.

Clinical Trial Description

This is a Phase 1, 3-way, crossover, randomized, open-label study in healthy subjects designed to compare the bioavailability of belumosudil (previously known as KD025) tablet formulation administered in the fed and fasted states and to assess the relative bioavailability of belumosudil tablet and capsule formulations in the fed state. The primary objective of the study is to determine the PK parameters of belumosudil tablet formulation in the fed and fasted states. The secondary objectives of the study are: (1) to assess the relative bioavailability of a tablet (test) to capsule (reference formulation of belumosudil; (2) to assess and compare the variability in the maximum concentration (Cmax) and area under the concentration-time curve (AUC) for belumosudil treatments (belumosudil 200 mg tablet in the fasting state, belumosudil 200 mg tablet in the fed state, and belumosudil as two 100 mg capsules in the fed state); and (3) to provide additional safety and tolerability information for belumosudil. This is a single-center, open-label, randomized, single-dose, 3-period, 3-way, crossover study in healthy subjects. In each of 3 study periods, each subject receives 1 of the following single-dose treatments: - Regimen A: Belumosudil 200 mg tablet in the fasted state - Regimen B: Belumosudil 200 mg tablet in the fed state - Regimen C: Belumosudil 200 mg as two 100-mg capsules in the fed state Subjects are randomized to receive 1 dose of investigational product (IP; belumosudil tablet or capsule) in the morning of Day 1 in a randomized manner following an overnight fast or a high-fat breakfast. Administration is performed on Day 1 with an appropriate interval between subjects based on logistical requirements. Start time is determined based on logistics. Subjects undergo a screening visit in the 21 days preceding first dose. Subjects are admitted to the clinical unit on the evening prior to dosing (Day -1), remain on site until 24 hours post-dose, and return to the clinic at 36 and 48 hours post-dose for PK assessments. There is a minimum washout period of 6 days between each dose administration. All other meals are standardized for each of the in-clinic phases of the 3 treatment periods. Each period follows the same study design. The randomized cohorts for the 3-periods were as follows: - Cohort ABC: Regimen A (Period 1); Regimen B (Period 2); Regimen C (Period 3) - Cohort BCA: Regimen B (Period 1); Regimen C (Period 2); Regimen A (Period 3) - Cohort CAB: Regimen C (Period 1); Regimen A (Period 2); Regimen B (Period 3) A follow-up call is made 3 to 5 days after the final dose of IP. Planned enrollment is 24 subjects to insure there are 20 evaluable subjects. A subject is considered evaluable if (s)he completes treatment with fasted and fed tablet formulations (Regimens A and B) without major protocol deviations. ;

Related Conditions & MeSH terms

• Bioavailability

• NCT number: NCT02557139
• Study type: Interventional
• Source: Kadmon Corporation, LLC
• Status: Completed
• Phase: Phase 1
• Start date: September 2015
• Completion date: October 12, 2015